Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
GYRE has been in the news recently: Castle Biosciences' COO, Kristen Oelschlager, was awarded the 2024 Jon W. McGarity Arizona Bioscience Leader of the Year for her effective leadership. Additionally, Arsenal Biosciences, Inc. appointed Nate Hardy as CFO to strengthen its financial strategy starting October 7, 2024.
📡️ Health Care
In The News
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
